Key Highlights
- Phase 2 NEST data showed no colorectal cancer recurrences at a median follow-up beyond two years.
- 59% of patients had a pathologic response and 88% achieved pre-surgical ctDNA clearance in pMMR/MSS tumors.
- Results support a planned global Phase 3 trial, ROBBIN, in curative-intent MSS colon cancer.
- Data was disclosed on August 26, 2026.
Neoadjuvant Immunotherapy in a Hard-to-Treat Tumor Type
Agenus Inc. (NASDAQ:AGEN) disclosed Phase 2 data on August 26, 2026 from its NEST study, evaluating neoadjuvant botensilimab plus balstilimab — meaning the combination is given before surgery — in colorectal cancer. The tumors studied were classified as pMMR/MSS, a subtype that has historically shown limited responsiveness to immunotherapy, making the result notable within the broader colorectal cancer treatment landscape.
At a median follow-up of more than two years, the study reported no recurrences of colorectal cancer among treated patients, a durability signal that stands out in a tumor subtype where relapse after surgery remains a persistent clinical challenge.
Depth of Response
The data also showed a 59% pathologic response rate, indicating that treatment produced measurable tumor changes to the extent surgical pathology could confirm, and an 88% rate of pre-surgical ctDNA clearance — a blood-based measure of circulating tumor DNA — in the pMMR/MSS population. Clearance of ctDNA ahead of surgery is increasingly used as an early marker of treatment effect in solid tumors, since it can reflect a reduction in detectable disease burden before pathology is available.
Next Step: Phase 3 ROBBIN
Based on the NEST results, Agenus (NASDAQ:AGEN) is planning a global Phase 3 trial named ROBBIN, which will test the botensilimab-balstilimab combination in curative-intent MSS colon cancer — meaning the surgery is intended to remove the cancer entirely, with the drug combination used beforehand to improve outcomes. A Phase 3 program of this scope would represent a substantially larger and more definitive test of the neoadjuvant approach.
Market Reaction
Despite the positive trial data, Agenus (NASDAQ:AGEN) shares fell 5.33% to $7.81, with the company's market Capitalization at approximately $351.61 million. The decline illustrates that clinical results and near-term share price moves do not always align, particularly for small-capitalization biotechnology names where broader capital and financing considerations can weigh on sentiment independent of pipeline progress.
What did the Agenus NEST trial show?
The Phase 2 NEST trial showed no colorectal cancer recurrences at a median follow-up beyond two years, with a 59% pathologic response rate and 88% pre-surgical ctDNA clearance in pMMR/MSS tumors.
What is the next trial planned for this combination?
Agenus (NASDAQ:AGEN) is planning a global Phase 3 trial called ROBBIN in curative-intent MSS colon cancer.
Why is the pMMR/MSS subtype significant?
pMMR/MSS colorectal tumors have historically shown limited response to immunotherapy, so a strong result in this subtype is considered notable.






Please wait processing your request...